Document is current
Any future updates will be listed below
-
Authors
Hubig, Lena T.
Smith, Timothy
Williams, Emma
Powell, Lauren
Johnston, Karissa
Harris, Linda
L’Italien, Gilbert
Coric, Vladimir
Lloyd, Andrew J.
Lo, Siu Hing
-
Funding
Funding for this research was provided by:
Biohaven Pharmaceuticals Inc
- License Information
-
More Information
Article History
Received: 16 June 2022
Accepted: 18 July 2022
First Online: 8 August 2022
Declarations
:
: This study was reviewed and approved by the WIRB-Copernicus Group Independent Review Board (tracking number: 20211304). All participants provided written online consent before completing the survey.
: Not applicable.
: GL, LH, and VC are employed by and own stock/stock options in Biohaven Pharmaceuticals Inc. SHL, LTH, and EW are employees of Acaster Lloyd Consulting Ltd. AJL is an employee and shareholder of Acaster Lloyd Consulting Ltd. Acaster Lloyd Consulting Ltd. were commissioned by Biohaven Pharmaceuticals Inc. to conduct the study. TS is an employee of StudyMetrix LLC and has received consulting fees from Biohaven Pharmaceuticals Inc. in the conduct of this study. LP and KJ are employees of Broadstreet HEOR, which received payment by Biohaven Pharmaceuticals Inc. in the conduct of this study.
